Item 7.01 Regulation FD Disclosure.
Greenwich LifeSciences, Inc. (the "Company") intends to conduct meetings with
third parties in which its corporate slide presentation will be presented. A
copy of the presentation materials is attached as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
The information in this Item 7.01 and the document attached as Exhibit 99.1 are
being furnished and shall not be deemed "filed" for purposes of Section 18 of
the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), nor
otherwise subject to the liabilities of that section, nor incorporated by
reference in any filing under the Securities Act of 1933 or the Exchange Act,
except as shall be expressly set forth by specific reference in such a filing.
Item 8.01 Other Events.
On October 6, 2020, the Company announced the completion of the manufacturing of
the GP2 active ingredient for its planned Phase III clinical trial. On October
7, 2020, the Company announced that it was selected to present at the 2020 BIO
Investor Forum conference to be held virtually from October 13-15, 2020 and will
be participating at the BIO-Europe partnering conference to be held virtually
from October 26-29, 2020. On October 8, 2020, the Company announced that two
abstracts have been accepted for presentation at the upcoming San Antonio Breast
Cancer Symposium (SABCS), including two corresponding posters. Copies of the
press releases are attached hereto as Exhibits 99.2, 99.3 and 99.4,
respectively, and are incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description
99.1 Greenwich LifeSciences, Inc. Corporate Presentation
99.2 Press release dated October 6, 2020
99.3 Press release dated October 7, 2020
99.4 Press release dated October 8, 2020
© Edgar Online, source Glimpses